Regeneron hands off ex-US rights for cholesterol disorder drug to rare disease specialist Ultragenyx

Regeneron has held high hopes for evinacumab, a rare cholesterol disorder drug that earned a first-in-class nod from the FDA early last year, as a centerpiece of its cardiometabolic franchise. Now, the company is tapping an ultra-rare specialist to take evinacumab to the next level abroad.

Regeneron will receive $30...

Click to view original post